## SUPPLEMENTAL DATA

Supplemental Table. Tissue biodistribution of <sup>111</sup>In-tVCAM-4 in nude mice 4 hours after probe injection.

Tissue	Mean (% dose injected/g)	Std Dev
Kidney	44.24	12.62
Liver	0.68	0.06
Pancreas	0.74	0.23
Spleen	0.41	0.08
Lung	0.38	0.03
Heart	0.22	0.04

**Supplemental Figure 1.** SPECT images of <sup>111</sup>In-tVCAM-4 peptide 4 hours after IP injection into saline control injected (Control) or tumor-bearing (SKOV3ip1) animals. Representative coronal and sagittal sections taken from the same plane of each animal are displayed.

**Supplemental Figure 2.** LP9 cells treated as for Figure 3B were subjected to qRT-PCR for VCAM-1 and GUSB (housekeeping control). Data represent the  $\Delta$ - $\Delta$ C<sub>t</sub> values for each point normalized to the untreated control.

**Supplemental Figure 3. (A)** SPECT/CT images were collected weekly starting 1 week after tumor initiation (week 0) as described in Figure 4A; weeks 0, 1 and 2 indicate time after carboplatin treatment. Representative coronal and sagittal SPECT images (same plane for each animal) of <sup>111</sup>In-tVCAM-4 peptide obtained 4 hours after IP injection are depicted. **(B)** Correlative histology demonstrating VCAM-1 expression on the mesothelium (arrows). At week 0, A2780 and A2780Cis show similar VCAM-1 reactivity; weeks 1 and 2 show increased VCAM-1 reactivity in mice containing A2780Cis cells compared to those with A2780 cells. Note the lack of reactivity in the control slide obtained from a mouse without tumor cells. 60X images with 20X insets.